Consilium advises on €100m IPO for molecular firm Biocartis

Healthcare specialist Consilium Strategic Communications advised Biocartis on its successful IPO, which listed on Euronext Brussels earlier this week.

Consilium Strategic Communications: Consulted on the €100m IPO of Biocartis
Consilium Strategic Communications: Consulted on the €100m IPO of Biocartis

Molecular diagnostics firm Biocartis raised €100m (£72m) from institutional and retail investors, floating a week ahead of schedule.

Hilde Windels, managing director and chief financial officer of Biocartis, was impressed with the advice provided by the agency and will continue work with it to deliver financial and investor-related comms.

"Working with Consilium, we were able to find the right way to tailor our investment message to specifically address each of our critical audiences, whether it be specialist institutional investors, generalists, retail or media," Windels said.

Consilium Strategic Communications has had a busy start to 2015, winning four clients in the first quarter. In February it advised Horizon Discovery, a medical research company, on its £68.6m IPO on AIM.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.